KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Dividends Paid - Preferred: 2015-2017

Historic Dividends Paid - Preferred for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Sep 2017 value amounting to -$123.0 million.

  • Teva Pharmaceutical Industries' Dividends Paid - Preferred rose 63.82% to -$123.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$749.0 million, marking a year-over-year increase of 20.49%. This contributed to the annual value of $261.0 million for FY2016, which is 1640.00% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Dividends Paid - Preferred stood at -$123.0 million for Q3 2017, which was up 64.35% from -$345.0 million recorded in Q2 2017.
  • In the past 5 years, Teva Pharmaceutical Industries' Dividends Paid - Preferred registered a high of $65.0 million during Q4 2016, and its lowest value of -$346.0 million during Q1 2017.
  • Its 3-year average for Dividends Paid - Preferred is -$232.4 million, with a median of -$290.0 million in 2015.
  • The largest annual percentage gain for Teva Pharmaceutical Industries' Dividends Paid - Preferred in the last 5 years was 333.33% (2016), contrasted with its biggest fall of 18.47% (2016).
  • Teva Pharmaceutical Industries' Dividends Paid - Preferred (Quarterly) stood at $15.0 million in 2015, then spiked by 333.33% to $65.0 million in 2016, then spiked by 63.82% to -$123.0 million in 2017.
  • Its last three reported values are -$123.0 million in Q3 2017, -$345.0 million for Q2 2017, and -$346.0 million during Q1 2017.